Abcellera Biologics Inc ABCL

$11.80 -0.88 (-6.94%)

Valuation

Market cap
3,618,010,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,112,100
Avg volume
7,113,298
Day's range
$11.72 – $12.68
Shares out
306,611,000
Stochastic %K
4%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Oct 18, 11:00 PM
$ABCL Insiders were buying above the offering price. I think anyone that wants out doesn’t fully understand the potential.
0 replies
Stocktradesmoon Oct 18, 10:59 PM
$ABCL Gotta love it when executives and institutions are frantically buying shares at every opportunity and are unwilling to unload anything when they’re able to. Even after such a beastly run up in prices ytd $ABCL
0 replies
Stocktradesmoon Oct 18, 10:37 PM
$ABCL The true competitiveness of $ABCL lies not in AI… but in the combination of biology, experimental data, and talent. If the ability to repeatedly produce new drugs is proven, I believe it has potential for more than a ten-bagger. 🧬🚀 The AI<>Biology show is on. Unit economics are healthy at the end of the value chain. Making unit economics work backwards is an engineering problem. Biology will deliver most of the returns in the stock market going forward now.
0 replies
Stocktradesmoon Oct 18, 10:33 PM
$ABCL I think most people don’t realize that the data we have right now, if it holds, is transformative for menopause industry. Transformative. That’s not even taking into account breast and prostate and ovarian cancer. It’s a big deal‼️ The pipeline story already has a strong data point. ABCL635 met both primary goals in its Phase 2 trial for moderate-to-severe VMS, and the stock jumped 33% intraday on the readout, near 40% at the peak. ABCL635 only entered clinical trials in July 2025 and it's already AbCellera's most advanced asset. It still needs a bigger pivotal trial before any filing, and full 12-week data are the next benchmark and it’s this WEEK in a few days🔥 Thursday, October 22, 2026 TMS!! $ABCL is not one molecule with one readout. It is a discovery engine that partners pay to use, across many programmes running at once. A single failure is a data point, not an ending. That is a different risk shape than single asset biotech.
0 replies
Stocktradesmoon Oct 18, 10:23 PM
$ABCL Don't forget what Carl said about listening to others, both in life and in markets, unless you want to be blown off course... Imagine getting the chance to own Regeneron right before it exploded into a giant... that's the opportunity you have today. At a similar crossroad, Regeneron did not have AI as a tailwind, they had less money and more debt, and slower initial clinical validation, and was significantly less internally diversified both technologically and programmatically. Nobody here can convince you of this... You have to do the work to research and develop your own conviction! Simply borrowing it from others will not suffice... I jumped down the rabbit hole and researched, read and watched everything‼️ Now I can't stop buying, and I look at anyone trimming this name and can't help but feel bad for them...truly. I remain 100% full ported on ABCL ... 🫡 TLDR: I will gladly buy your dollars for pennies
0 replies
Stocktradesmoon Oct 18, 10:08 PM
$ABCL UPDATE ABcellera 🔥 🔥 🔥!!! I’ve shared my short-term PT expectations and resistance levels before. Adding this: If the market fully prices in ABCL’s 5–10 year potential during this rally, we could see a sharp move into the $36–52 range, followed by a meaningful pullback afterward (low probability scenario). That said, the long-term potential remains massive. Success in internal programs + external partnerships could reasonably drive this to a $100+ stock by 2029. It’s a matter of execution and time.
0 replies
Stocktradesmoon Oct 18, 10:03 PM
$ABCL $11.80’sss Get in NOW or Miss OUT!! BIG CATALYST EVENT this Week in 4 days 2026 TMS Menopause Convention Conference 🔥!!! As I was listening to past conferences this snippet from JP Morgan held on Jan 15, 2025 stands out for me. Hansen’s closing remarks talk about the next 5-10 years. He’s not thinking about the next quarter or trying to appeal to the short term. He’s a very long thinker. This is before ABCL635 target was disclosed and in the clinic. And well before Phase 2 data. What I find most interesting. He says that if you look at the history of the industry, it would be hard for you to find a set up as promising as where AbCellera was at the time. I think this applies to today. They have the technology, they have the funds and they have the desire to see it through. I think we are at an inflection point for the company and that the next 5-10 years is going to be truly remarkable for AbCellera. Good luck everyone!
0 replies
Stocktradesmoon Oct 18, 9:56 PM
$ABCL 🧬 $13 Dollar Resistance $13 dollars is in sight. But this guy won't open the door without a fight. 😂 No matter how many times you knock, it slams the brakes at $13.18 every time. Still, it didn't back down and climbed back up to $12.86. Now what we need isn't the chart—it's a reason to break through. 🔥 October 22 TMS — ABCL635 ..it’s this WEEK 4 days AWAY‼️ The market's already seen the Phase 2 topline. This time, it needs to show something more in 12-week DATA durability, sleep, safety, and redosing. The chart brought us right to the door at $13 dollars. The one to kick it down is the data. Alright, 635. Let's open that door. 🚪💥 $ABCL #AbCellera #ABCL635
0 replies